Investor Relations

Our Mission and Vision

NKGen Biotech’s mission is to improve patient outcomes in neurodegenerative disease and cancer by developing safe and effective cellular therapies that leverage the power of a patient’s immune system. NKGen’s vision is to become the global leader in NK cell therapies.

Corporate Profile

NKGen Biotech is a clinical-stage biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. NKGen’s product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells with increased activity (defined by parameters such as cytotoxicity, cytokine production and activating receptor expression) as compared to the starting NK cell population.

SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. NKGen believes that SNK cells have the potential to deliver transformational benefits to patients with both neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, and cancer.